Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
BioTraceIO360 received FDA 510(k) clearance for kidney ablation, expanding its previous liver tumor ablation indication. The platform standardizes minimally invasive care, enhancing treatment planning ...
FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years and older. Recommended dosages are 395 mg/4800 units every 3 weeks or 790 mg/9600 units ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
FloStent enabled catheter-free voiding in men with BPH-related urinary retention, showing potential as an interim solution before TURP. At three months, 72.7% of patients remained catheter-free, with ...
Rhonda Stamey, APRN, is a key member of the Advanced Therapy Center Medical Team at First Urology, where she plays an active role in advancing the treatment of prostate cancer. She provides expert ...
FGFR inhibitors are vital in bladder cancer treatment but face challenges due to significant toxicities, limiting long-term use. Dabogratinib selectively targets FGFR3, aiming to reduce toxicities ...
Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies. Apolo emphasized the value of having robust monotherapy data before advancing into ...
Biparametric MRI, omitting gadolinium contrast, is noninferior to multiparametric MRI for detecting significant prostate cancer, offering a faster, cheaper alternative. The PRIME trial involved 490 ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback